Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

Chemicals in flavoured vapes potentially ‘very toxic when heated’ - Tech & Science Daily

New research suggests chemicals in flavoured vapes could be highly toxic when heated.

Evening Standard

Astrazeneca Withdraws Vaxzevria Vaccine Due To Decline In Demand

AstraZeneca withdraws Vaxzevria vaccine due to decreased demand from newer, more effective mRNA vaccines. Strategic shift in global vaccination landscape.

Top News

The Best European Stocks to Buy

European stocks are cheaper than their U.S. counterparts, and there are plenty of high-quality companies to choose from. Here's how you can find them.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca withdraws Covid vaccine worldwide due to 'surplus'

The pharma giant says the decision was made due to the availability of superior vaccines

Evening Standard

AstraZeneca Withdraws Covid Vaccine As Demand Dives

Anglo-Swedish drugmaker AstraZeneca on Wednesday said it was withdrawing Covid vaccine Vaxzevria, one of the first produced in the deadly pandemic, citing "commercial reasons" following a slump in demand.

International Business Times

Afternoon Update: US paused weapons shipment to Israel; Hunter Valley bus driver plea deal; and the life expectancy of cats

Senior US official says shipment of bombs was paused last week after review of weapons that might be used in Rafah

The Guardian - AU

AstraZeneca withdraws COVID-19 vaccine worldwide, cites commercial reasons

The pharmaceutical giant AstraZeneca's COVID-19 vaccine is being withdrawn worldwide after the company acknowledged for the first time in court documents that it can cause a rare and dangerous side effect, according to a report in the British Newspaper 'The Telegraph'. Read further on Dynamite News:

Dynamite News

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca withdraws Covid-19 vaccine worldwide, citing surplus of newer vaccines

Pharmaceutical company says newer shots led to decline in demand for AstraZeneca vaccine, which is no longer being manufactured or supplied

The Guardian - AU

No adverse effects reported from COVID vaccines in India: V. K. Saraswat

No adverse effects have been reported in India with regard to the vaccines used for battling COVID-19, senior scientist and NITI Aayog member V. K. Saraswat said here on Saturday.

The Hindu

Is This Dividend Stock a Buy Now?

With a robust portfolio, this top pharma stock is a good mix of growth and income.

Barchart

Families 'give up legal action' against Astrazeneca after Covid vaccine blood clot deaths

Twelve families have dropped their cases, according to reports

Evening Standard

In India, all vaccine-related AEFI are routinely monitored and COVID is no exception, says health expert

All ‘Adverse Events Following Immunisation’ (AEFI) after COVID-19 vaccinations continue to be monitored, a senior official said.

The Hindu

"Safety is primary focus for all our vaccines": Covaxin-developer Bharat Biotech amid reports on AstraZeneca vaccine

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." Read further on Dynamite News:

Dynamite News

Covishield | Plea in Supreme Court for probe panel for vaccine’s ‘risk factors’

Controversy over Covishield safety reaches Supreme Court, petition seeks expert panel to study risk factors and vaccine consequences.

The Hindu

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.

Evening Standard

AstraZeneca's £18.7m boss Soriot bounces back as pharma giant reveals 18% sales growth

Soriot came under fire this month for his £18.7 million pay packet

Evening Standard

There's still plenty of shares to like on the poor old FTSE 100

City Voices: Taken together, London’s top flight mightn’t look so appealing. But that doesn’t mean that all UK stocks should be written off.

StockNews.com

3 Biotech Stocks with Potential Gains - Watch or Buy?

The biotech industry’s growth prospects look promising due to advanced technologies like AI, the growing popularity of tailored treatments, a rise in chronic diseases, and higher R&D spending. Let's analyze the investment prospects of biotech stocks Innoviva (INVA), Organogenesis Holdings (ORGO), and Compugen (CGEN). Read more.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

The danger in saying yes to Pascal Soriot’s pay rise at AstraZeneca

Despite rebellion, approval of £18.7m package opens door to likelihood of US-style executive pay elsewhere

Top News

Astrazeneca Shareholders Approve CEO Pay Policy For 2024

AstraZeneca shareholders approve 2024 pay policy, showing confidence in CEO Soriot's leadership and company's future growth.

The Guardian - UK

AstraZeneca CEO’s £18.7m pay approved despite shareholder rebellion

Third of voters reject Pascal Soriot’s deal but some say it is deserved as he had been ‘massively underpaid’

Evening Standard

FTSE 100 Live 11 April: Shares edge lower before ECB rates ca, Lok'nStore bought out by Shurgard for £378m

A new pay deal for AstraZeneca boss Pascal Soriot and the fallout from yesterday’s US inflation shock are among areas of focus for London traders.

Barchart

Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.

Roll Call

Experts say Medicaid rebate change is behind inhaler price cuts - Roll Call

Three inhaler manufacturers will cap patient copays for their inhalers at $35 a month and lower the list prices of some of those products.

Investors Business Daily

Fusion Rockets 99%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover

AstraZeneca said Tuesday is would acquire Fusion Pharmaceuticals for $2 billion upfront. The biotech stock nearly doubled.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.